Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 20;18(14):1135-1149.
doi: 10.4244/EIJ-D-22-00070.

Transcatheter interventions for heart failure

Azeem Latib  1 , Mohammad Hashim Mustehsan  1 , William T Abraham  2 , Ulrich P Jorde  1 , Jozef Bartunek  3
Affiliations
Review

Transcatheter interventions for heart failure

Azeem Latib et al. EuroIntervention. .

Abstract

Despite significant advances in the medical management of patients living with heart failure, there continues to be significant morbidity and mortality associated with the condition. There is a growing need for research and development of additional modalities to fill the management and treatment gaps, reduce hospitalisations and improve the quality of life for patients living with heart failure. In the last decade, there has been a rapid rise in the use of non-valvular catheter-based therapies for the management of chronic heart failure to complement existing guideline-directed management. They target well-defined mechanistic and pathophysiological processes critical to the progression of heart failure including left ventricular remodelling, neurohumoral activation, and congestion. In this review, we will explore the physiology, rationale, and current stages of the clinical development of the existing procedures.

PubMed Disclaimer

Conflict of interest statement

A. Latib has served on advisory boards or as a consultant for Medtronic, Boston Scientific, Philips, Edwards Lifesciences, Abbott, and Ancora Heart. U.P. Jorde has served on advisory boards for Edwards Lifesciences and Abbott; has been a consultant for Edwards Lifesciences and Abbott and receives travel support from Ancora Heart. W.T. Abraham has received personal fees from Vectorious Medical Technologies and V-Wave. J. Bartunek serves on the Trial Steering Committee for Occlutech and as a member of the Clinical Events Committees and Data Safety Monitoring Boards of the Vectorious HF trials. He receives personal fees from Occlutech. M.H. Mustehsan has no conflicts of interest to declare.

Figures

Central illustration
Central illustration. Novel therapies for the management of heart failure by mechanism.
Yellow/green: Devices for management of chronic heart failure. Blue/purple: Devices for management of acute decompensated heart failure. CRS: cardiorenal syndrome
Figure 1
Figure 1. Implantable haemodynamic monitors.
A) CardioMEMS (adapted from Abbott). B) Cordella (adapted from Endotronix). C) V-LAP (adapted from Vectorious Medical Technologies)
Figure 2
Figure 2. Interatrial shunt devices.
A) InterAtrial Shunt Device (adapted from Corvia Medical). B) V-Wave Shunt System (adapted from V-Wave). C) Atrial Flow Regulator (adapted from Occlutech). D) Transcatheter Atrial Shunt System (adapted from Edwards Lifesciences)
Figure 3
Figure 3. Devices for renal artery perfusion.
A) Aortix Percutaneous Mechanical Circulatory Support System (adapted from Procyrion). B) Reitan Catheter Pump (adapted from Cardiobridge). C) Second Heart Assist Device (adapted from Second Heart Assist)
See this image and copyright information in PMC

References

    1. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, Smith SC, Subačius H OBTAIN Investigators. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol. 2015;66:1431–41. - PMC - PubMed
    1. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of Enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10. - PubMed
    1. Cohn JN, Tognoni G Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75. - PubMed
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17. - PubMed
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371:993–1004. - PubMed